Protocol Ledger

NCT03958877 · Phase III · ACTIVE NOT RECRUITING

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Interventional Phase III clinical trial protocol NCT03958877 sponsored by Biogen in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-10-18 Enrollment: 152 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03958877
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)152 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03958877
Protocol FieldVerified Registry Value
NCT IdentifierNCT03958877
Consolidated Lead SponsorBiogen
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment152 participants (ACTUAL)
Registered Start Date2019-10-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03958877
Hospital Research SiteLocationSite Profile
UC San Diego Health and Moores Cancer CenterSan Diego, CAOpen Hospital Dossier ->
Fakultni nemocnice Hradec KraloveHradec Králové, CzechiaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Biogen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI